Tag Archives: adalimumabbwwd

FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira

FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira Print this page INCHEON, Korea – July 24, 2019 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hadlima (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab)i, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult… Read More »